NitroMed Prices BiDil At $5-$10 Per Day Wholesale Acquisition Cost
This article was originally published in The Pink Sheet Daily
Executive Summary
The heart failure therapy, which is approved for use in self-identified black patients, will arrive in pharmacies the week of July 11 with a wholesale acquisition cost of $1.80 per tablet. NitroMed is planning a patient assistance program for uninsured patients.
You may also be interested in...
NitroMed Plans Targeted BiDil Launch To Select Physicians; Sales Team Boasts Cardio Experience
BiDil launch targets physicians treating African-American heart failure patients over age 45. Sales force consists of reps with average 5.7 years cardiovascular sales experience.
NitroMed Plans Targeted BiDil Launch To Select Physicians; Sales Team Boasts Cardio Experience
BiDil launch targets physicians treating African-American heart failure patients over age 45. Sales force consists of reps with average 5.7 years cardiovascular sales experience.
NitroMed Ramps Up For Solo BiDil Launch In July
NitroMed’s 190-person sales force has begun detailing the heart failure therapy, according to CEO Loberg. The firm expects to launch BiDil in two to four weeks, without a partner. Labeling provides defense against generic substitution, Loberg says.